We identified GSK-J1 as a potent epigenetic inhibitor that specifically targets the histone demethylases UTX (KDM6A) and JMJD3 (KDM6B) with synergistic potential in HNSCC cells when combined with irradiation. Here, KDM6A is linked to head and neck squamous cell carcinoma.